Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: Brattleboro Retreat Board Chair Elizabeth Catlin said the organization is ready to work "with all willing partners" to help it achieve financial stability. The board began considering its options last week when the state of Vermont rejected a $2 million request for additional funding. "In recent years, the Brattleboro Retreat's board and its management team have taken a number of creative, cost-conscious steps to reshape and modernize hospital operations while meeting the rising tide of soaring labor costs," said Catlin's statement. "The Brattleboro Retreat's quality of care, even with these financial pressures, continues to be excellent." The facility serves more than half the people in Vermont who need psychiatric care and provides all of the child and adolescent psychiatric care in the state. It also provides addiction services including inpatient and outpatient rehabilitation, and treatment services for those who get Suboxone, a prescription medication used to treat opioid addictions. If it closes, the letter said that would mean finding services for 2,500 inpatients annually as well as filling new gaps for Suboxone treatment services, residential programs for children and meeting other critical health needs. On Sunday, Vermont Human Services Secretary Michael Smith said he had rejected a request for an additional $2 million in funding from the retreat. That request would be added to a financial package valued at an estimated $16 million for new beds and a recent rate increase valued at an estimated $3.5 million per year. Smith said he rejected the request in part because he believes it would constitute a taxpayer bailout of financial miscalculations by Brattleboro Retreat's management. But Josephson said the state wasn't paying it enough to care for the patients the state wants cared for. On Friday, Josephson sent a letter Friday to Smith and Gov. Phil Scott, a Republican, that said the facility cannot continue operating without more support from the state. He said the board had authorized him to begin planning for the sale or closure of the retreat "in the very near future." Claim: Psych hospital's financial woes won't stop services, for now.

Answer: Officials at Vermont's largest private psychiatric hospital said Monday they are dedicated to providing quality mental health care to patients amid the possibility of the facility shuttering or being forced into a sale.

Question: Paragraph: London's Metropolitan Police said the company had been charged with seven counts of supplying a medicinal product which was not of the nature or quality specified in the prescription. It was also accused of failing to take all reasonably practicable steps to ensure that patients were not infected by contaminants. The north London company said in a statement: "As founders of ITH we have every sympathy for all the families affected, regardless of the cause. However, we are disappointed by the decision to charge the company and will vigorously defend this case." The police investigation was launched in September 2014 following the death of a baby three months earlier at London's Guy's and St Thomas' hospital. The death of a second baby at the same hospital and a third at the Rosie Maternity Hospital in Cambridge, central England, in June 2014 were then also investigated. The inquiry followed an outbreak of a bacterial infection that affected some babies receiving Total Parental Nutrition (TPN), an intravenous feed. The seven babies involved in the investigation, including the three who died, had all received the feed. The investigation established that the cause of death of the first baby could be linked to TPN, although the deaths of the other two were not found to be linked. Five hospitals in total were involved in the investigation, the other three being Russells Hall Hospital in Dudley, Luton and Dunstable Hospital and Lister Hospital in Stevenage, all in central England. ITH Pharma, which was founded in 2008, said it had manufactured more than 1.4-million components of TPN since its launch and was the sole commercial supplier of reactive feeding solutions to the National Health Service. "This product has helped thousands of extremely vulnerable infants survive premature and complex births," it said. The case is due to start at Westminster Magistrates' Court in London on Dec. 17. Claim: UK police charge pharmaceutical company over hospital baby deaths.

Answer: Police said on Wednesday they had charged pharmaceutical company ITH Pharma with a number of offences as part of an investigation into the deaths and illnesses of seven babies at several hospitals.

Question: Paragraph: EpiPens deliver potentially lifesaving doses of the generic drug epinephrine, via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction. "We are shipping product. Currently there is no shortage in the U.S.," said Steve Danehy, a spokesman for Pfizer Inc (PFE.N), which produces the global supply of EpiPens for Mylan out of a single facility near St. Louis, Missouri. Mylan is in charge of managing allocation of the EpiPen supply, Danehy said in an email to Reuters. It was not immediately clear why Canada and the UK would be subject to a shortage at this time. A Mylan spokeswoman was not available for comment. Mylan's EpiPen sales practices in the United States sparked public outrage in 2016 as consumers saw the price for a pack of two auto-injectors rise sixfold to $600 in less than a decade, making the devices unaffordable for a growing number of families. Since then, the company has launched a generic version of EpiPen for half the price, though the U.S. market is still the most lucrative. Meridian Medical Technologies Inc, the unit of Pfizer that manufactures EpiPens, has been hit by a series of manufacturing problems. In March 2017, Mylan recalled tens of thousands of devices after complaints that some had failed to activate. In September, Meridian received a warning letter from the U.S. Food and Drug Administration. The FDA said Meridian had failed to thoroughly investigate product failures, including EpiPen products that were associated with patient deaths and severe illnesses. It said the company failed to take corrective actions until FDA's inspection. At the time, Mylan said it did not anticipate any impact on EpiPen supply based on the warning letter. But on Thursday, Pfizer Canada said it was "experiencing supply constraints" for EpiPens used by both adults and children "due to delays at the manufacturing facility," as well as problems in sourcing a component for the device from an outside supplier. There are no alternatives on the market in Canada, federal health officials there said. They advised patients and caregivers to use expired EpiPens in an emergency if they have nothing else on hand, and then call 911. "Pfizer understands and regrets the challenges that these ongoing supply constraints pose to patients and the healthcare community," the company said in a statement on its website. On Friday, the UK website for EpiPen notified consumers of "intermittent supply constraints" for the adult injector. It said the next shipment to EpiPen's distributor in the country was expected toward the end of April. Mylan's revenue from EpiPen dropped sharply over the last year due to increased competition, the launch of its own cheaper generic and higher rebates that it has had to pay to as a result of a settlement for overcharging the U.S. government. Claim: EpiPen shortages seen in Canada, UK but U.S. supply intact.

Answer:
Mylan N.V.'s (MYL.O) emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.